Pricing Log in Create free account
Saturday 17 October 2026 Export INMB’s income statement to Excel — free account

INmune Bio, Inc.

INMB Healthcare Biotechnology

INmune Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $50,000.00, up 257.1% from fiscal 2024. In the quarter to June 2026, revenue grew 8.70%, EPS grew 95.2% and free cash flow grew 55.4%, each against the same quarter a year earlier.

1.57 0.08 −4.85%
Market cap
$45.8M
P/E
0.0×
Fwd P/E
−1.8×
Dividend yield
—
F-score
4/9
Altman Z
−10.46
Beneish M
−3.67
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 7.37%

Capital & Financial Ratios $m

Market Cap 45.80
Revenue 0.14
Net Income (18.42)
Free Cash Flow (16.43)
Net Debt (18.41)
Current Ratio 4.04 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (1.79) (negative: loss-making)
P/S ratio 310.73 (above 10: high)
P/B ratio 2.06
Past 5Y EPS Growth —
This Y EPS Growth 70.43% (at or above 15%: strong)
Next Y EPS Growth (40.00%) (below 0%: weak)
Next Y revenue growth 18,980.00% (at or above 10%: strong)
Next 5Y EPS Growth 25.15% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 210×, against a ten-year median of 352×; over the ten years it ranged from 89.3× in 2026 to 1,506× in 2024.
P/S against its own 10 years 15.54%
10-year low 10-year high
P/B against its own 10 years 24.11%
10-year low 10-year high
EV/Sales against its own 10 years 24.27%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 36 21 25 18
Receivables 2 1 5 5
Inventory — — — —
Other — — — —
40 23 30 24
2023 2024 2025 Q'26
Payables 8 7 8 5
ST’ Debt 10 — — —
Other 0 1 — —
18 7 8 6

Compound Annual Growth %

10y 5y 3y
Sales — 35.37% (48.87%)
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — (9.50%) (26.85%)

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’25 0 — — — 0
’24 0 — — — 0
’23 0 0 0 0 0
’22 0 0 0 0 0
’21 0 — 0 0 0
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (3) (3) — — —
’25 (7) (7) (5) (3) (23)
’24 (7) (8) (7) (11) (33)
’23 (1) (3) (4) (3) (12)
’22 (9) (5) (3) (6) (23)
’21 (5) (6) (8) (10) (29)
’20 (1) (2) (4) (2) (9)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (3) (4) — — —
’25 (7) (8) (6) (3) (24)
’24 (7) (8) (7) (11) (33)
’23 (1) (3) (4) (3) (12)
’22 (9) (5) (3) (6) (23)
’21 (5) (21) (8) (10) (44)
’20 (1) (2) (4) (2) (9)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.20) (0.05) — — —
’25 (0.43) (1.05) (0.24) (0.18) (1.86)
’24 (0.61) (0.50) (0.60) (0.40) (2.11)
’23 (0.36) (0.36) (0.48) (0.47) (1.67)
’22 (0.39) (0.38) (0.43) (0.32) (1.52)
’21 (0.32) (0.44) (0.55) (0.55) (1.88)
’20 (0.19) (0.20) (0.36) (0.24) (1.01)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — 3.51 2.20 9.23 4.63 5.87 4.32 1.38

Analyst estimates 2026–2028

Powerpack
High — — — 11.50 24.42 30.37 11.78 11.78 14.74 11.64
People
People Employees — 2 3 4 5 10 10 17 22 21
Revenue/emp, $m — 0.00 0.00 0.00 0.00 0.02 0.04 0.01 0.00 0.00
Income, $m
Income, $m Revenue — — — — 0 0 0 0 0 0
Gross margin, % — — — — 100.00 100.00 100.00 100.00 100.00 100.00
EBT 0 (1) (12) (8) (12) (30) (27) (30) (42) (46)
EBT margin, % 0.00 0.00 0.00 0.00 (109,990.91) (16,762.43) (7,299.20) (19,360.00) (300,685.71) (91,866.00)
Net income 0 (1) (12) (8) (12) (30) (27) (30) (42) (46)
Depreciation — — — — — 0 0 0 0 0
Per share, $
Per share, $ Revenue 0.00 0.00 0.00 0.00 0.00 0.01 0.02 0.01 0.00 0.00
Earnings (0.02) (0.13) (1.43) (0.75) (1.01) (1.88) (1.52) (1.67) (2.11) (1.86)
Cash flow (0.03) (0.12) (0.24) (0.52) (0.75) (1.77) (1.27) (0.67) (1.67) (0.91)
Capex 0.00 (0.02) 0.00 0.00 0.00 (0.93) 0.00 0.00 0.00 (0.04)
Free cash flow (0.03) (0.13) (0.24) (0.52) (0.75) (2.70) (1.27) (0.67) (1.67) (0.95)
Book value (0.01) 2.76 1.91 2.30 3.23 4.97 3.35 2.08 1.61 0.95
Shares, m 11 7 9 10 12 16 18 18 20 25
Valuation, ×
Valuation, × P/E — — — — 0.00 0.00 0.00 0.00 0.00 0.00
P/S — — — — 0.00 857.41 321.63 1,301.59 710.98 286.09
P/B — — — — 5.33 2.05 2.00 5.40 2.90 1.64
EV/Sales — — — — 0.00 543.28 221.48 1,149.65 588.45 138.83
EV/FCF — — — — (20.64) (3.66) (3.65) (14.87) (2.31) (0.79)
Cash, $m
Cash, $m Operating cash flow 0 (1) (2) (5) (9) (29) (23) (12) (33) (23)
Capex — 0 — — — (15) — — — (1)
Free cash flow 0 (1) (2) (5) (9) (44) (23) (12) (33) (24)
Balance, $m
Balance, $m Working capital 0 2 0 7 22 78 54 21 15 21
Total debt 0 — — 0 0 15 15 10 — —
Net debt 0 (1) 0 (7) (22) (60) (37) (26) (21) (25)
Shareholders’ equity 0 18 17 24 39 80 60 37 32 24
Returns, %
Returns, % ROA (2.94) (8.82) (69.54) (36.71) (37.16) (43.16) (30.04) (43.24) (87.16) (127.75)
ROIC 0.00 (3.67) (47.54) (28.88) (45.10) (91.35) (71.62) (162.87) (238.53) 0.00
ROE (3.09) (9.26) (71.82) (38.25) (38.80) (51.00) (38.91) (61.59) (121.21) (165.16)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2025

Charts ten years each

INmune Bio, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
KLRS Kalaris Therapeutics Inc. $47.8M — (loss-making) — — n/m +11.91% (above 0%: growing) 0.00% 0.00% Compare
IBIO iBio, Inc. $47.6M — (loss-making) — (loss-making) +100.00% (above 0%: growing) n/m −35.33% (below 0%: shrinking) 100.00% 0.00% Compare
CLNN Clene Inc. $47.0M — (loss-making) — (loss-making) +233.33% (above 0%: growing) n/m +45.43% (above 0%: growing) 60.00% (5,941.11%) Compare
TVGN Tevogen Inc. $46.1M — (loss-making) — — n/m +5.78% (above 0%: growing) — 0.00% Compare
INMB INmune Bio, Inc. $45.8M — (loss-making) — (loss-making) +8.70% (above 0%: growing) n/m +55.39% (above 0%: growing) 100.00% 0.00%
IMA ImageneBio, Inc. $45.7M — (loss-making) — (loss-making) −60.08% (below 0%: shrinking) n/m +23.76% (above 0%: growing) 100.00% 0.00% Compare
SER Serina Therapeutics, Inc. $45.5M — (loss-making) — (loss-making) +2,500.00% (above 0%: growing) n/m −76.82% (below 0%: shrinking) 100.00% 0.00% Compare
ANVS Annovis Bio, Inc. $44.8M — (loss-making) — — n/m −329.18% (below 0%: shrinking) — 0.00% Compare
ALDX Aldeyra Therapeutics, Inc. $44.5M — (loss-making) — — n/m +46.09% (above 0%: growing) 0.00% 0.00% Compare
Median of peers $45.9M — — +166.67% — +8.85% 80.00% 0.00%

All 614 Biotechnology stocks →

INmune Bio, Inc. (INMB) key facts

  • Strength: INmune Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $50,000.00, up 257.1% from fiscal 2024.
  • INmune Bio, Inc. (INMB) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, INMB traded at $1.57, a market capitalization of $45.8 million.
  • Return on equity was −165.2% and debt-to-equity 0.00.
  • Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −10.46 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

INmune Bio, Inc. (INMB) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/INMB · Data as of Mar 31, 2025 · For information only; not investment advice. · © 2026 stockrow.com